SCHEMBL6985515

SCHEMBL6985515

CCOC(=O)c1cnc2c3c(c(C)cc2c1O)C(=O)C(C(=O)OCC)C=N3

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TP53 P04637 4/20 0.34
MAPT P10636 3/20 0.34
KDM4E B2RXH2 3/20 0.34
GLA P06280 2/20 0.34
GAA P10253 2/20 0.34
THRB P10828 1/20 0.34
CCNB2 O95067 1/20 0.34
CDK1 P06493 1/20 0.34
CCNB1 P14635 1/20 0.34
CCNA2 P20248 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
CCNB3 Q8WWL7 1/20 0.34
DPP4 P27487 5/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7798795 0.83 KMT2A (0.39) KMT2AMEN1NPC1RAB9ATP53
SCHEMBL6201826 0.71 TP53 (0.57) KMT2AMEN1NPC1RAB9ATP53
SCHEMBL11240555 0.71 THRB (0.57) KMT2AMEN1NPC1RAB9ATP53
SCHEMBL730189 0.69 MAPK1 (0.46) KMT2AMEN1NPC1RAB9ATP53
SCHEMBL25504851 0.69 KMT2A (0.40) KMT2AMEN1NPC1RAB9ATP53
SCHEMBL14358395 0.68 DPP4 (0.52) KMT2AMEN1MAPTKDM4EGAA
SCHEMBL538577 0.67 KMT2A (0.46) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL6288997 0.67 KMT2A (0.45) KMT2AMEN1NPC1RAB9ATP53
SCHEMBL26632758 0.67 MAPT (0.47) KMT2AMEN1NPC1RAB9ATP53
SCHEMBL31255110 0.67 MAPT (0.47) KMT2AMEN1NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 KMT2A 1250/4885MEN1 2187/4885NPC1 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.